Embecta Corporation EMBC

PARSIPPANY, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: Wells Fargo 2026 Healthcare ConferenceManagement will host one-on-one investor meetings on Wednesday, September 9, 2026, at the Encore Boston Harbor Hotel in Everett, Boston, MA.J.P. Morgan 4th Annu

Moby summary of Embecta Corp.'s Q3 2026 earnings call

Embecta Corp (EMBC) beats expectations with a $50 million sequential revenue jump, raises adjusted EPS guidance, and advances its Owen Mumford integration despite persistent U.S. market pressures.

PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results. Visit the company’s Investor Relations website at http://investors.embecta.com to view the detailed third quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and l

PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2026 to stockholders of record at the close of business on August 27, 2026.About embectaembecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company,

PARSIPPANY, N.J., July 23, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, August 7, 2026. Those who would like to participate may access the live webcast

Embecta is in focus after one fair value estimate was reset from US$15.00 to US$4.00, which highlights how much some analysts have reworked their view of what the stock might be worth under updated assumptions. That shift sits alongside commentary pointing to a tougher setup for medtech valuations, higher inflation and capital flowing toward data center stocks, all of which are shaping how investors think about Embecta today. As you read on, you will see what is driving this evolving...

PARSIPPANY, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that Nimish Muzumdar has been named the company’s Senior Vice President and President, North America, effective June 15, 2026. Mr. Muzumdar will be responsible for leading the United States and Canada commercial teams and executing the region’s long-term growth str

S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively.

With an upside potential of 32.01%, Embecta Corp. (NASDAQ:EMBC) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, Bank of America analyst Travis Steed lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $3 from $11 while maintaining an Underperform rating on the shares. Following meetings with […]

The transaction supports Embecta’s plan to diversify by supplying drug delivery solutions to pharmaceutical partners.

Embecta bought the company, which has an auto-injector platform, to expand outside of diabetes care.